文献速递浆细胞疾病

新诊断与复发难治多发性骨髓瘤中基于微小残留病与影像学指导的巩固治疗策略

Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma.
PubMed 文献 · Br J Haematol · 2022-05-18

该研究纳入102例多发性骨髓瘤患者(新诊断57例、复发难治45例),采用二代流式细胞术(NGF)联合正电子发射断层扫描或弥散加权磁共振成像评估微小残留病(MRD)。45%患者达到NGF与影像双阴性;29例接受MRD触发巩固治疗者中51%实现MRD转阴、21%血清学反应改善,且无进展生存期(PFS)优于标准治疗(p=0.04)。

要点

  • NGF联合功能影像可提高MRD评估全面性,尤其适用于既往治疗线数≥4的重度预处理患者。
  • MRD触发巩固治疗可使部分患者实现MRD转阴或血清学反应改善。
  • MRD触发巩固治疗较标准治疗延长无进展生存期(p=0.04)。

核心结论

  • NGF联合影像学评估有助于识别残留病灶,尤其在重度预处理的多发性骨髓瘤患者中;基于MRD的巩固治疗可能改善无进展生存期。

研究设计与样本

  • 单中心经验性研究,纳入102例多发性骨髓瘤患者,其中新诊断57例、复发难治45例;影像学检查采用正电子发射断层扫描或弥散加权磁共振成像。

主要发现

  • 45%的患者达到NGF与影像双阴性,8%的患者仅NGF阴性,40%的患者仅影像阴性。
  • 影像阳性而NGF阴性的情况在既往治疗≥4线的重度预处理患者中较新诊断患者更常见(p < 0.01)。
  • 29例接受MRD触发巩固治疗的患者中,51%实现MRD转阴,21%血清学反应改善。
  • MRD触发巩固治疗组较标准治疗组无进展生存期更优(p = 0.04)。

临床怎么用

  • 作者认为,NGF联合影像学评估尤其有助于重度预处理多发性骨髓瘤患者的残留病灶检测;基于MRD的巩固治疗可能改善无进展生存期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurement of minimal residual disease (MRD) by next-generation flow cytometry (NGF) is an important tool to define deep responses in multiple myeloma (MM). However, little is known about the value of combining NGF with functional imaging and its role for MRD-based consolidation strategies in clinical routine. In the present study, we report our experience investigating these issues with 102 patients with newly diagnosed (n = 57) and relapsed/refractory MM (n = 45). Imaging was performed using either positron emission tomography or diffusion-weighted magnetic resonance imaging. In all, 45% of patients achieved MRD-negativity on both NGF and imaging (double-negativity), and 8% and 40% of patients were negative on either NGF or imaging respectively. Thus, in a minority of patients imaging was the only technique to detect residual disease. Imaging-positivity despite negativity on NGF was more common in heavily pretreated disease (four or more previous lines) compared to newly diagnosed MM (p < 0.01). Among the 29 patients undergoing MRD-triggered consolidation, 51% responded with MRD conversion and 21% with improved serological response. MRD-triggered consolidation led to superior progression-free survival (PFS) when compared to standard treatment (p = 0.04). In conclusion, we show that combining NGF with imaging is helpful particularly in patients with heavily pretreated MM, and that MRD-based consolidation could lead to improved PFS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Böckle D, Tabares P, Zhou X, et al. Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma. Br J Haematol. 2022. PMID: 35582835. doi:10.1111/bjh.18249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。